Not reported.

Thrombocytopenia. Nausea, vomiting, abdominal pain, anorexia, hepatotoxicity.

Should severe or debilitating GI effects occur, reduce dosage or discontinue the drug based on benefit-to-risk considerations.

Arrhythmias, hypotension.

Pericarditis, pleuritis and ascites, myosis with intersitial shadowing on chest X-ray and elevated sedimentation rates.

Hypoxemia and jaundice with oral amrione.

Fever, chest pain, burning at site of injection.

Hypersens to amirinone or bisulfites.

Special precautions:

Do not use amrinone in patients with severe aortic or pulmonic valvular disease in lieu of surgical relief of the obstruction.

It may aggrevate outflow tract obstruction in hypertropic subaortic stenosis.

Arrhythmias,thrombocytopenia is more common in patients receiving prolonged therapy. Amrinone not recommended in acute mycardial infaction .

If acute marked alterations in liver enzymes occur together with clinical symptoms,discontinue amrione.

Monitor fluid and electrolyte changes and renal function during amrinone therapy.

Indications:

For short term management of CHF.

Dosage-

Initial therapy- 0.75mg/kg IV Bolus slowly over 2 to 3 minutes.Maintain infusion 5 to 10mcg/kg/min.

Do not exceed a total daily dose of 10mg/kg.

Pharmacology:

Amrinone is a positive inotropic agent with vasodilator activity,different in structure and mode of action from either digitalis glycosides or catecholamine. Its mechanism is not fully elucidated.

Pharmacokinetics:

Amrinone has a volume distribution of 1.2 litres/kg and a distribution half-life of about 4.6 minutes. It is 10 to 49% protein bound.

Not available

Pregnancy:

Use during pregnancy only if the potential benefit justifies the potential risks to the fetus.

Lactation:

Excercise caution when administering to nursing women.